Announcements Trials
Browse Landscape

Phase

Phase NA 26Phase 2 6Phase 1/2 3Phase EARLY_PHASE1 2Phase 1 2Phase 3 1

Status

Completed 592Unknown 143Recruiting 129Active not recruiting 109Terminated 85Not yet recruiting 41Withdrawn 25Suspended 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Myasthenia Gravis 2Leukemia, Myeloid, Acute 2Radiodermatitis 1Neurotoxicity Syndromes 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Gallbladder Neoplasms 1Fibrosis 1Esophageal Squamous Cell Carcinoma 1Depression 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Carcinoma 1Breast Neoplasms 1Breast Cancer Metastatic 1

Interventions

exemestane 1Tamoxifen 1Letrozole 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Enrolling by invitation × Breast Neoplasms × Clear all
NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Tolmar Inc.

Phase 3 Enrolling by invitation
250 enrolled
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡